NEOTEC programme selects Sequentia Biotech’s project Tricopharming


Our Tricopharming project has been selected for financing by the CDTI (Centre for Industrial Technological Development) in the framework of its NEOTEC programme. NEOTEC aims to support the creation and consolidation of technology-based companies.

Our tricopharming R&D division exploits plants’ potential to produce valuable medicinal compounds in their trichomes or plant hairs. Our first project, Artepharming, focuses on increasing the yield of artemisinin production by the Artemisia annua plant. Artemisinin is a molecule that has been used for decades to treat malaria and has the potential to tackle many other diseases.

Thanks to our technology and the NEOTEC contribution, we look forward to increasing the natural production of this molecule in a sustainable, environmentally-friendly and competitive way.